STX.L • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold STX.L in your mock portfolio yet.
Shield Therapeutics remains loss-making, as indicated by its negative EPS and negative P/E ratio. The lack of positive earnings suggests that the current valuation is driven more by expectations than by underlying profitability. Without evidence of improving margins or a clear path to sustained profits, the financial profile is fundamentally weak.
The stock has rallied strongly, rising 29.8% over the last month, and is trading well above its 200-day moving average, indicating a solid upward trend. An RSI of 56.02 suggests the stock is in neutral-to-positive momentum territory without being overbought. Overall, technicals point to bullish price action with room for further moves if positive catalysts persist.
Alternative data for Shield Therapeutics is relatively muted, with flat web traffic, no active hiring, and only modest growth in social media following. These signals neither strongly confirm nor contradict the recent price strength. They suggest limited visible expansion activity or broadening investor/customer engagement at this time.
Shield Therapeutics’ stock is showing strong positive technical momentum, but this is not yet supported by profitability or compelling alternative data growth signals. The setup looks more like a sentiment- or catalyst-driven move on a fundamentally weak earnings base. Overall, the outlook is neutral: technically constructive but fundamentally risky until earnings and growth visibility improve.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: